Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02297438
What this trial is testing

Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Who this might be right for
Breast Neoplasms
Pfizer 340
Early research (Phase 1)Study completedNCT01862081
What this trial is testing

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Who this might be right for
Breast Cancer, Non-small Lung Cancer
Genentech, Inc. 80
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Early research (Phase 1)Study completedNCT01209195
What this trial is testing

MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Who this might be right for
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Merrimack Pharmaceuticals 41
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774624
What this trial is testing

Study of SKB103 in HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 140
Not applicableStudy completedNCT03154190
What this trial is testing

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Who this might be right for
Acute Myeloid LeukemiaBrain GlioblastomaEstrogen Receptor Negative+64 more
Stanford University 128
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Testing effectiveness (Phase 2)UnknownNCT03750396
What this trial is testing

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Who this might be right for
Breast CancerRecurrent Breast CancerStereotactic Body Radiotherapy+3 more
Gangnam Severance Hospital 110
Post-approval studies (Phase 4)WithdrawnNCT01156961
What this trial is testing

The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

Who this might be right for
Breast Cancer
Hoffmann-La Roche
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT06907043
What this trial is testing

PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors
Eikon Therapeutics 130
Testing effectiveness (Phase 2)Study completedNCT01147484
What this trial is testing

Foretinib in Patients With Recurrent/Metastatic Breast Cancer

Who this might be right for
Recurrent Breast Cancer
NCIC Clinical Trials Group 47
Testing effectiveness (Phase 2)Study completedNCT03394027
What this trial is testing

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Who this might be right for
Triple Negative Breast CancerEndometrial CancerHormone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Large-scale testing (Phase 3)Study completedNCT02225470
What this trial is testing

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Who this might be right for
HER2-Negative Breast CancerTriple Negative Breast CancerBreast Cancer+2 more
Eisai Co., Ltd. 530
Testing effectiveness (Phase 2)Ended earlyNCT00622466
What this trial is testing

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of Texas Southwestern Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT01256762
What this trial is testing

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Locally Recurrent or Metastatic Breast Cancer
Geron Corporation 166
Not applicableStudy completedNCT05677308
What this trial is testing

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Who this might be right for
Breast Cancer
AstraZeneca 61
Large-scale testing (Phase 3)Ended earlyNCT03786094
What this trial is testing

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Recurrent Breast Cancer
Spexis AG 432
Next Page